Early-onset forms of Alzheimer disease (AD) have been associated with pathogenic variants in the APP , PSEN1 , and PSEN2 genes. Mutations in presenilin-1 ( PSEN1 ) account for the majority of cases of autosomal dominant AD. Numerous phenotypes have been associated with PSEN1 -pathogenic variants, including cerebellar ataxia and spastic paraplegia. Here, we describe a patient with early-onset AD presenting with extrapyramidal symptoms and supranuclear gaze palsy, mimicking progressive supranuclear palsy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WAD.0000000000000503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial.
Lancet Neurol
February 2025
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada; Department of Cognitive Neurology, St Joseph's Health Care London, London, ON, Canada. Electronic address:
Background: No treatments exist for apathy in people with frontotemporal dementia. Previously, in a randomised double-blind, placebo-controlled, dose-finding study, intranasal oxytocin administration in people with frontotemporal dementia improved apathy ratings on the Neuropsychiatric Inventory over 1 week and, in a randomised, double-blind, placebo-controlled, crossover study, a single dose of 72 IU oxytocin increased blood-oxygen-level-dependent signal in limbic brain regions. We aimed to determine whether longer treatment with oxytocin improves apathy in people with frontotemporal dementia.
View Article and Find Full Text PDFPerformance of a Two-Week Rehabilitation Improves Motor Function in Inpatients with Progressive Supranuclear Palsy: A Pre-Post Study.
Brain Sci
January 2025
Department of Neurology, NHO Higashinagoya National Hospital, Nagoya 465-8620, Japan.
: Progressive supranuclear palsy (PSP) is characterized by early postural instability and gait dysfunction, with frequent falls. Rehabilitation is an important therapeutic approach for motor dysfunction in patients with PSP. However, no conclusions have yet been drawn regarding the beneficial effects of rehabilitation in PSP, including the optimal duration of rehabilitation and differences in treatment effects among PSP subtypes.
View Article and Find Full Text PDFAdvanced Magnetic Resonance Imaging for Early Diagnosis and Monitoring of Movement Disorders.
Brain Sci
January 2025
Unidad de Trastornos del Movimiento y Sueño, Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, Mexico City 14080, Mexico.
Advanced magnetic resonance imaging (MRI) techniques are transforming the study of movement disorders by providing valuable insights into disease mechanisms. This narrative review presents a comprehensive overview of their applications in this field, offering an updated perspective on their potential for early diagnosis, disease monitoring, and therapeutic evaluation. Emerging MRI modalities such as neuromelanin-sensitive imaging, diffusion-weighted imaging, magnetization transfer imaging, and relaxometry provide sensitive biomarkers that can detect early microstructural degeneration, iron deposition, and connectivity disruptions in key regions like the substantia nigra.
View Article and Find Full Text PDFCognitive impairment in PSP compared with PD: assessment by clinical subtype and longitudinal change.
BMJ Neurol Open
January 2025
Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.
Background: Longitudinal studies investigating cognitive function changes in patients with progressive supranuclear palsy (PSP) are limited. The variability of cognitive impairment across clinical subtypes of PSP remains unclear.
Objective: This study aimed to compare the longitudinal changes in cognitive function between patients with PSP and Parkinson's disease (PD) and to assess differences in cognitive impairment among PSP subtypes.
Frequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy/corticobasal syndrome.
Parkinsonism Relat Disord
January 2025
Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan. Electronic address:
Serum anti-IgLON5 antibodies, which were tested in 223 patients meeting the diagnostic criteria for progressive supranuclear palsy/corticobasal syndrome (PSP/CBS), were negative in all patients. Our study suggests that the frequency of anti-IgLON5 disease is extremely rare in patients with typical presentation of PSP/CBS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!